Apixaban (Eliquis) treats/prevents selected clots. Confidence: high for licensed roles and warnings; independent comparative benefit remains unestablished in this evidence set. NHS overview.
- Bleeding, head injury and extra medicine need prompt assessment.
- Carry the anticoagulant alert card and show it before procedures.
- Routine INR testing is not the monitoring plan.
- Children’s preparations and feeding restrictions differ by country.
- Sponsored trials do not supply an independent superiority verdict.
Table of contents
- Evidence summary
- Products
- How it works
- Care
- Lifestyle and supplements
- Human studies
- Urgent warnings
- Interactions
- Eligibility
- Taking and continuity
- Limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Product roles | Current UK/US originals. | Maker sources, 4/D. | Licence/safety context; no independent superiority. |
| Monitoring | SPS framework. | Commissioned NHS; contributor/study chains unclosed. | Individual surveillance, not home thresholds. |
| Human comparisons | ARISTOTLE and AMPLIFY. | BMS/Pfizer; author commercial ties, 4/D. | Design reviewed; efficacy excluded. |
| Feeding | UK leaflet, US guide, SPS. | Maker data or unresolved milk-study finance. | Country-specific instructions; infant outcomes unclosed. |
| Dispensing | England PCA. | Agency public/service finance; allocation unclosed. | Items, not people or worldwide popularity. |
Products
US forms: 2.5/5 mg tablets; 0.5 mg suspension tablets; 0.15 mg ELIQUIS SPRINKLE capsules. Never swallow suspension forms intact. US preparations.
UK 2.5 mg Eliquis: adult non-valvular atrial fibrillation (AF), DVT/PE and elective hip/knee prophylaxis; paediatric safety/efficacy not established. UK indications.
PLGB numbers can remain after UK-wide conversion; the prefix alone cannot establish GB-only licensing today. Current territorial rules.
England’s 2025/26 community dataset records 11,005,705 apixaban prescription items, BNF 0208020Z0. This is a dispensing count, not a number of patients, proof of benefit or a global prescribing rank. Original row 246.
The PCA covers prescriptions dispensed in the community in England. It does not measure all hospital prescribing, individual adherence, or the condition for which each item was used. Counting scope.
This guide covers the individual ingredient. The anticoagulant overview addresses the broader class. Current local packs and availability require pharmacy confirmation.
How it works
Apixaban inhibits clotting factor Xa, interfering with a step in clot formation. “Blood thinner” is a common description, not a claim that it changes blood into a thinner liquid. Protection requires the prescribed treatment plan; feeling well does not establish that clot risk has disappeared. Mechanism and continuity.
AF care can separately address heart rate/rhythm and clot-related stroke risk. Anticoagulation is one component; rhythm procedures and other medicines serve different purposes. A prescription for clot protection is not a promise to eliminate palpitations or replace assessment of an underlying heart condition. Different treatment roles.
Deep vein thrombosis (DVT) is a clot in a vein, often a leg. Assessment may require imaging and consideration of its cause; treatment and recovery plans depend on the clinical situation. Walking and other prevention measures are supportive care, not a way to decide independently whether anticoagulation is unnecessary. Venous-clot care.
Care
US: paediatric venous thromboembolism (VTE) after initial anticoagulation, from birth; not recommended below 2.6 kg. US age boundary.
NHS mentions selected children above 35 kg; that advice does not establish a particular UK pack’s paediatric licence. Prescribing versus licence.
US dialysis recommendations derive from pharmacokinetics; dialysis patients were not enrolled in efficacy/safety studies. Strong combined inducers must be avoided. US limitations.
For direct oral anticoagulants (DOACs), SPS describes baseline blood count, kidney/liver function, weight and subsequent review. Older/frail people, organ impairment, illness and interacting medicines may need closer checks. Lack of routine international normalised ratio (INR) testing does not mean no monitoring or that a home laboratory cutoff can select a dose. Professional surveillance.
SPS distinguishes routine review from concern about occult bleeding, including unexplained haemoglobin decline. Monitoring should have an identified clinician responsible for interpreting results and reviewing treatment. Its expert-opinion framework is not a universal interval, a home creatinine calculator or an automatic stop/restart rule. Interpreting results.
Lifestyle and supplements
AF advice includes physical activity within clinical limits, a balanced diet, weight management, avoiding smoking and excessive alcohol. Discuss exercise when symptoms occur. These measures support broader care; they do not answer which anticoagulant an individual needs or prove a herb can replace the prescribed plan. Lifestyle context.
Supplements can interact with medicines and affect bleeding or anaesthesia. Disclose them before procedures; a “natural” or “certified” description cannot establish compatibility, ingredient consistency or safety in pregnancy and children. This dated safety source does not establish a supplement substitute for anticoagulation. Supplement boundaries.
St John’s wort and anti-inflammatory painkillers (NSAIDs) can interact. Discuss prescribed, over-the-counter and herbal products with the pharmacist before adding them. NHS compatibility.
Ask who will check a proposed supplement against the actual prescription and pack. No supplement brand, personal replacement plan or bleeding-risk score is recommended here.
Human studies
ARISTOTLE randomised 18,201 adults with AF/flutter and additional stroke risk to masked apixaban or warfarin. It tested non-inferiority before superiority, with stroke/systemic embolism as the primary outcome. Blinded adjudication and a monitoring board addressed methodological risks. Selected valve disease and severe renal impairment were excluded, limiting generalisation. Original design.
Sponsor representatives participated in steering; BMS and Duke analysed data. The published declarations identify BMS/Pfizer support, commercial investigator ties and BMS employee-stock interests. Masking improves design but does not make the study financially independent. Its results are therefore not adopted as an independent superiority claim. Oversight and declarations.
AMPLIFY randomised adults with acute VTE in a masked six-month comparison with enoxaparin/warfarin. Recurrence/VTE death and bleeding were distinct endpoints. Sponsors maintained data, academics accessed it through sponsors, and Pfizer employees were authors. Selected high-bleeding-risk and severe-renal conditions were excluded. Original methods.
The original names BMS/Pfizer support and investigators’ commercial relationships; editorial assistance is acknowledged without a specified payer. Complete individual forms and protocol access were not obtained. The selected publisher-indexed original text supports this design/finance description, not an independently cleared outcome estimate or a home conversion regimen. Financial and access limits.
Urgent warnings
Severe bleeding requires stopping the DOAC and immediate medical assessment. This MHRA notice supports that warning; its older reversal-agent availability statements are not used as current universal advice. Emergency care takes priority over routine medicine-continuity instructions. Severe bleeding warning.
Severe or recurrent bleeding: contact NHS 111 or attend A&E immediately. A significant head blow, major accident or bleeding that will not stop also needs immediate assessment. Blood in urine/stool, black stool, blood in vomit or cough, and extensive bruising warrant clinical review; these are class warning signs, not proof of drug causation. Class bleeding signs.
Sudden severe breathlessness, chest/upper-back pain, a very fast heartbeat or collapse: call 999 or attend A&E in the UK; do not drive yourself. These may signal a lung clot (PE) or another serious condition even in someone prescribed anticoagulation. Emergency symptoms.
Throat/tongue swelling, severe breathing/swallowing difficulty or suspected anaphylaxis: call 999/local emergency services. Emergency allergy.
After spinal/epidural procedures, leg weakness, numbness/tingling or bowel/bladder-control problems require calling the doctor immediately; spinal complications can cause paralysis. Spinal warning.
US: collapse, seizure, breathing difficulty or unresponsiveness after overdose requires 911. US overdose urgency.
Interactions
UK: strong combined CYP3A4/P-glycoprotein inhibitors are not recommended; strong inducers are not recommended for DVT/PE treatment. Professional interactions.
CYP3A4 and P-glycoprotein affect medicine metabolism/transport. SPS identifies bleeding concerns with NSAID painkillers, antiplatelets, SSRI/SNRI antidepressants and selected antiarrhythmics or antibiotics. Reduced exposure may occur with enzyme-inducing medicines. Some reported interactions remain theoretical or uncertain; uncertainty does not establish safety. Other anticoagulants need specialist-controlled exceptions. The prescriber/pharmacist must reconcile the complete list, indication, renal function and actual product. Professional compatibility.
Do not substitute apixaban for heparin in unstable PE needing thrombolysis/embolectomy. Specialist combinations and acute care.
Pharmacist: reconcile all products; omissions are not clearance.
Eligibility
UK: active significant bleeding, bleeding-risk liver coagulopathy and major-bleeding-risk lesions contraindicate use; prosthetic valves are not recommended. Restrictions.
MHRA advises against DOAC use in APS, particularly triple-positive disease. This is attributed safety guidance, not an independently cleared apixaban trial comparison or an instruction to switch at home. Dated APS warning.
UK leaflet: do not take in pregnancy; pregnancy during use requires immediate doctor contact. Doctor decides treatment versus breastfeeding. UK reproduction.
US professional: pregnancy use not recommended; patient guide: do not breastfeed. US reproduction.
SPS does not recommend apixaban while breastfeeding. Its limited milk evidence involved four women; none of their infants breastfed, leaving infant absorption and outcomes unknown. The broader framework applies to healthy full-term infants; premature/unwell babies or multiple medicines require specialist advice. Published milk transfer is not proof of infant safety. Evidence limits.
Taking and continuity
Too many Eliquis tablets: doctor immediately; bring the pack, even empty. Discuss routine stopping; unsure about missed tablets, ask doctor/pharmacist. UK patient instructions.
More than prescribed: NHS 111 now, before symptoms. Carry the alert card; show clinicians/dentists before procedures. Bleeding or head injury also needs prompt advice. NHS taking and alert card.
For AF, stopping early can increase stroke risk. Discuss interruptions and refills; keep a written medicine, vitamin and supplement list for appointments and emergencies. Continuity and medicine list.
Urgent warnings override routine continuity; bringing the pack must not delay care.
Limits
FDA announced US safety concerns about Andexxa in December 2025 and its manufacturer’s end to US sales. This concerns that reversal product, not withdrawal of apixaban. Local bleeding management is a clinical emergency decision; an old leaflet cannot establish present reversal availability in every country. Current US boundary.
The FDA ledger dates withdrawal of that indication December 23, 2025. It does not establish another country’s licensing or pharmacy stock. Specific status.
Animal evidence does not establish human benefit or infant safety. Preclinical boundary.
Yellow Card accepts suspected medicine problems; a report alone cannot establish causation or frequency. Urgent treatment precedes reporting. Reporting service.
This article separates licensed instructions from conflict-screened comparative efficacy. It does not calculate a benefit estimate, rank medicines or infer that a financial conflict proves a result false.
Funding and source roles
Research funding at a glance
44 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS apixaban | National route below; contributor/page/trial payments unclosed. | UK. | Tier 2; clinical context | B provisional. January 21, 2026; public education, not efficacy clearance. |
| Eliquis UK SmPC | BMS/Pfizer EEIG holder; seller alliance and paid eMC routes below. | UK product record; holder Dublin, Ireland. | Tier 4; maker source | D. July 28, 2026; professional restrictions, not independent comparative benefit. |
| Eliquis 5 mg leaflet | BMS/Pfizer EEIG holder; Catalent Italy, Pfizer Germany and Swords Ireland maker alternatives. Pack/capital chains unclosed. | UK product record; holder Dublin, Ireland. | Tier 4; maker source | D. May 2026; August 12 hosting. Patient warnings. |
| US Eliquis label | BMS/Pfizer market; alliance below. Pack plant unclosed. | US product. | Tier 4; maker source | D. August 2026 professional; May 2025 patient guide. Efficacy uncleared. |
| SPS DOAC monitoring | NHS commissioned route below; exact contributors/bibliography finances unclosed. | England NHS service. | Tier 2; professional context | B provisional. August 6, 2026; expert framework, not home laboratory rules. |
| SPS anticoagulants and breastfeeding | Shared commissioning route; underlying milk-study finances unclosed. | England NHS service. | Tier 2; clinical context | C provisional. December 6, 2024; four women, no breastfed infants. |
| SPS DOAC interactions | Shared commissioning route; exact contributors/study payments unclosed. | England NHS service. | Tier 2; clinical context | B provisional. June 20, 2025; specialist compatibility advice, not exhaustive clearance. |
| AHFS apixaban | ASHP content, publishing/sponsor routes below; NLM hosts separately. | United States; Bethesda. | Tier 3; mixed institutional route | C provisional. October 15, 2025; exact author/trial interests unclosed. |
| NHS atrial fibrillation | National route below; contributor/trial interests unclosed. | UK. | Tier 2; clinical context | B provisional. January 13, 2025; broader care, not individual drug selection. |
| NHS DVT | National route below; contributor/trial interests unclosed. | UK. | Tier 2; clinical context | B provisional. April 30, 2026; urgent assessment and broader care. |
| NHS pulmonary embolism | National route below; author/trial finances unclosed. | UK. | Tier 2; emergency context | C provisional. May 2023; review overdue May 2026. No regimen adopted. |
| NHS anticoagulant side effects | National route below; contributor interests unclosed. | UK. | Tier 2; safety context | B provisional. September 9, 2024; class signs, not apixaban-specific rates. |
| NHS anaphylaxis | National route below; contributor interests unclosed. | UK. | Tier 2; emergency context | C provisional. June 2023; review overdue June 2026. |
| MHRA DOAC bleeding notice | Public/regulated-industry-fee route below; application/study allocations unclosed. | United Kingdom regulator. | Tier 3; regulatory context | C provisional. June 2020; bleeding warning only, not current reversal availability. |
| MHRA DOAC APS notice | Same regulator route; underlying trial financial chains unclosed. | United Kingdom regulator. | Tier 3; safety context | C provisional. June 2019; dated restriction, not independent apixaban outcome estimates. |
| MHRA UK-wide licensing | Public/industry-fee route below; exact application allocation unclosed. | United Kingdom regulator. | Tier 3; regulatory context | B provisional. March 12, 2025; retained PLGB prefixes do not alone establish current territorial scope. |
| FDA Andexxa safety update | Regulator finance below; AstraZeneca product discussed, not apixaban withdrawal. | United States FDA. | Tier 3; regulatory context | B provisional. December 18, 2025; jurisdiction-specific status, not independently cleared trial effect. |
| FDA withdrawn-indication ledger | Shared regulator route; exact application allocation unclosed. | United States FDA. | Tier 3; regulatory record | B provisional. Current original table; indication status, not local stock. |
| ARISTOTLE original, 2011 | BMS/Pfizer supported. Granger outside commercial grants/fees; BMS employees/stock and other author ties disclosed. Individual forms/receipts unclosed. | International trial; 39 countries. | Tier 4; manufacturer-funded trial | D. Actual 12-page NEJM reprint; design reviewed, comparative efficacy excluded. |
| AMPLIFY original, 2013 | BMS/Pfizer supported; Agnelli fees and Pfizer employee authors. Caudex editorial assistance acknowledged, payer unspecified. Full forms/receipts unclosed. | International adult VTE trial. | Tier 4; manufacturer-funded trial | D. Selected indexed original methods/declarations; full direct text/protocol inaccessible. Efficacy excluded. |
| BMS 2025 Form 10-K | Drug/alliance sales, public equity and debt. Pfizer funds 50–60% development; profits generally shared equally, country exceptions. Full beneficial investors/historical awards unclosed. | United States; Delaware incorporation, Princeton, New Jersey executive office. | Tier 4; seller filing | D. February 2026; selected actual alliance/revenue/identity notes. SEC hosting does not clear efficacy. |
| BMS subsidiary exhibit | Lists Swords Laboratories Unlimited Company, Ireland. Some immaterial subsidiaries omitted; no complete holder/pack capital chain. | Named Irish subsidiary. | Tier 4; seller-filed record | D. December 31, 2025 scope; legal identities, not every beneficial investor. |
| Pfizer 2025 annual review | Medicine sales, including Eliquis alliance/product revenue; shareholder capital and debt. Full beneficial investors and investigator receipts unclosed. | United States parent; jurisdiction separately below. | Tier 4; seller self-report | D. Selected full annual-review body; not complete audited Form 10-K access. |
| Pfizer 2025 filing identity | Company-filed public equity record; full direct filing exceeded reader size. No complete investor audit claimed. | United States; Delaware incorporation, 66 Hudson Boulevard East, New York executive office. | Tier 4; seller-filed record | D. Actual indexed original cover; selected access, not complete financial accounts. |
| NCCIH supplement safety | Congressional/gift routes below; Hopp/Shurtleff credited. Exact page/study interests unclosed. | United States NIH; Bethesda. | Tier 3; credited-source context | C provisional. January 2019; historical commercial reviewer work separately traced. No replacement efficacy. |
| Hopp official biography | Historical Shaman patent work, Phyto-Technologies herbal R&D and AMRI employment. Current royalties/page receipts unclosed. | United States; NCCIH, Bethesda. | Tier 3; own career record | B provisional. Biography, not complete financial declaration or 2019 page payment. |
| Shurtleff official biography | Federal NIH career; full outside interests and page payments unclosed. | United States; NCCIH, Bethesda. | Tier 3; own career record | B provisional. Current biography, not complete individual financial declaration. |
| NCCIH appropriations history | Congressional appropriations reported through FY2024. FY2026 enacted total and exact safety-page allocation not established here. | United States NIH/HHS; Bethesda. | Tier 3; own fiscal history | B provisional. Actual dated series; not a current operating-plan amount. |
| NCCIH gift fund | Authorized voluntary donations/bequests; gift account separate from Congressional appropriation. Named receipts/page funding unclosed. | United States NIH/HHS; Bethesda. | Tier 3; own financial authority | B provisional. Permission is not a specific corporate payment. |
| ASHP treasurer report, 2025 | FY2024 audit; meetings/exhibits, publishing, accreditation/consulting and investment income. FY2025 forecast/FY2026 budget are not actual results. | United States; Bethesda. | Tier 3; institutional fiscal report | B provisional. Actual 60-page packet, selected treasurer pages; page allocation and current full accounts unclosed. |
| ASHP corporate/advertising routes | Advertising, sponsorships, publishing partnerships and institutional sales offered. Exact AHFS-page receipts unclosed. | United States; 4500 East-West Highway, Bethesda. | Tier 3; own business disclosure | C provisional. Institutional marketing route, not a named apixaban-page sponsor. |
| ASHP historical corporate support | Amgen, Baxter, BD, BMS, Merck, Novartis, Pfizer and others listed for June 2019–May 2020. No current page payment inferred. | United States association; international companies. | Tier 3; own sponsor disclosure | C provisional. Dated educational support; not the 2026 donor ledger. |
| NLM FY2027 budget justification | FY2026 enacted versus FY2027 request; public institute. Gift authority. Exact hosted-source allocation unclosed. | United States NIH; Bethesda. | Tier 3; fiscal self-report | B provisional. Actual budget tables; hosting does not clear maker, society or trial interests. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| eMC publisher original | Datapharm Ltd owns eMC; pharmaceutical companies pay subscriptions to publish approved manufacturer/regulator material. Exact product fee and complete investors/revenues unclosed. | United Kingdom; Cassini Court, Randalls Way, Leatherhead, Surrey. | Tier 4; commercial publishing source | D. Own full publishing/finance/contact body read; hosting does not clear trial interests. |
| MHRA Yellow Card | Public/industry-fee route below; exact service funding unclosed. | United Kingdom regulator. | Tier 3; reporting context | B provisional. Suspected events, no causation/rate proof. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| FDA FY2026 operating plan | Public budget authority plus regulated-industry fees, including generic/prescription drug programmes. Exact application allocation unclosed. | United States FDA/HHS; Silver Spring, Maryland. | Tier 3; regulator fiscal report | B provisional. Actual five-page plan; public accountability and fee/policy incentives. |
| England PCA apixaban row | NHSBSA agency route below; exact programme allocation unclosed. | England community dispensing. | Tier 2; public statistics | B provisional. Actual Table 7 row 246; items, not patients or outcomes. |
| PCA methodology 2026 | Same agency financial route; exact data-production payments unclosed. | England community dataset. | Tier 2; public definitions | B provisional. June 2026; counting boundaries, no worldwide ranking. |
| NHS content policy | DHSC funds website; no advertising/corporate sponsorship stated. Clinical checks and staff-interest disclosure rules; exact apixaban contributors/receipts unclosed. | UK national website. | Tier 3; own policy record | C provisional. October 2022; review overdue October 2025. Individual receipts unclosed. |
Frequently asked questions
Does apixaban treat the heart rhythm itself? AF care separates rhythm/rate treatment from clot protection. Care roles.
Does no INR test mean no monitoring? No. Blood count, kidney/liver function and clinical review remain relevant. Monitoring framework.
Does milk transfer establish infant safety? No. SPS found no breastfed-infant outcome evidence in its limited apixaban data. Study limitations.
Can a supplement replace it? This review establishes no such replacement benefit; compatibility needs professional review. Safety limitations.
Sources and funding notes
Manufacturer-supported outcomes are excluded; funding does not prove false results.
ARISTOTLE: retained original reprint read.
AMPLIFY: selected publisher-indexed original; full article/protocol/forms inaccessible.
Product and feeding advice has country-specific dates.
Private awards, page payments, pack plants and complete beneficial investors remain unclosed. UK/US source concentration limits generalisation.
- NHS apixaban — Current safety
- Eliquis UK SmPC — Product restrictions
- Eliquis 5 mg leaflet — Patient instructions
- US Eliquis label — Restrictions/preparations
- SPS DOAC monitoring — Monitoring
- SPS anticoagulants and breastfeeding — Feeding evidence limits
- SPS DOAC interactions — Interactions
- AHFS apixaban — Mechanism and patient safety
- NHS atrial fibrillation — Rhythm versus clot protection
- NHS DVT — Venous clot context
- NHS pulmonary embolism — Emergency recognition
- NHS anticoagulant side effects — Bleeding recognition
- NHS anaphylaxis — Emergency recognition
- MHRA DOAC bleeding notice — Severe bleeding restriction
- MHRA DOAC APS notice — APS restriction
- MHRA UK-wide licensing — Product jurisdiction boundary
- FDA Andexxa safety update — Reversal-status boundary
- FDA withdrawn-indication ledger — Withdrawal date
- ARISTOTLE original, 2011 — AF trial methods and money
- AMPLIFY original, 2013 — VTE trial methods and money
- BMS 2025 Form 10-K — Alliance ownership and revenue
- BMS subsidiary exhibit — Manufacturer group boundary
- Pfizer 2025 annual review — Other alliance seller finance
- Pfizer 2025 filing identity — Parent jurisdiction
- NCCIH supplement safety — Supplement safety
- Hopp official biography — Credited reviewer provenance
- Shurtleff official biography — Other credited reviewer
- NCCIH appropriations history — Public supplement-source finance
- NCCIH gift fund — Possible gift channel
- ASHP treasurer report, 2025 — Content-owner revenue
- ASHP corporate/advertising routes — Commercial support channel
- ASHP historical corporate support — Historical named support
- NLM FY2027 budget justification — Public hosting finance
- NIH gift-administration policy — Gift authority, not receipt
- NHSBSA accounts, 2025/26 — Institutional finance
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- eMC publisher original — Label publisher revenue
- MHRA Yellow Card — Suspected-event reporting
- MHRA accounts, 2025/26 — Safety regulator finance
- FDA FY2026 operating plan — Regulator revenue route
- England PCA apixaban row — Dispensing count
- PCA methodology 2026 — Dataset limits
- NHS content policy — Shared website finance and governance
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.